Suchergebnisse - "Burggraaff, C N"

PubPharm (7)

1

Cost-Effectiveness of Shortening Treatment Duration Based on Interim PET Outcome in Patients With Diffuse Large B-cell Lymphoma

enthalten in: Clinical lymphoma, myeloma & leukemia | 2022

von Greuter, M. | Eertink, J. | Jongeneel, G. | +16

2

Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements

enthalten in: European journal of nuclear medicine and molecular imaging | 2022

von Eertink, J. | Arens, A. | Huijbregts, J. | +14

3

Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements

enthalten in: European journal of nuclear medicine & molecular imaging | 2021

von Eertink, J. | Arens, A. | Huijbregts, J. | +13

4

Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements

enthalten in: European journal of nuclear medicine and molecular imaging | 2021

von Eertink, J. | Arens, A. | Huijbregts, J. | +13

5

Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements

enthalten in: European journal of nuclear medicine and molecular imaging | 2021

von Eertink, J. | Arens, A. | Huijbregts, J. | +13

6

Optimal timing and criteria of interim PET in DLBCL : a comparative study of 1692 patients

enthalten in: Blood advances | 2021

von Eertink, J. | Burggraaff, C. | Heymans, M. | +22

7

FDG‐PET as a Biomarker of Response in DLBCL: the HOVON 84 Study Experience

enthalten in: Hematological oncology | 2017

von Burggraaff, C. | Vet, H. | Hoekstra, O. | +5

1
[1]